Search Results - "Gian, Victor G"

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures by Spigel, David R., Burris, Howard A., Greco, F. Anthony, Shih, Kent C., Gian, Victor G., Lipman, Andrew J., Daniel, Davey B., Waterhouse, David M., Finney, Lindsey, Heymach, John V., Hainsworth, John D.

“…BACKGROUND This study compared the efficacy and safety of treatment with erlotinib plus pazopanib versus erlotinib plus placebo in patients with previously…”
Get full text

Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI) by Spigel, David R., Rubin, Mark S., Gian, Victor G., Shipley, Dianna L., Burris, Howard A., Kosloff, Rebecca A., Shih, Kent C., Quinn, Raven, Greco, F. Anthony, Hainsworth, John D.

“…•Single agent sorafenib and the combination of sorafenib plus erlotinib had limited activity in patients with refractory NSCLC.•Continuation of erlotinib post…”
Get full text

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute by Hainsworth, John D., Thompson, Dana S., Bismayer, John A., Gian, Victor G., Merritt, William M., Whorf, Robert C., Finney, Lindsey H., Dudley, B. Stephens

“…This trial compared the efficacy and toxicity of standard first‐line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sorafenib in…”
Get full text

Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer by Spigel, David R, Anthony Greco, F, Waterhouse, David M, Shipley, Dianna L, Zubkus, John D, Bury, Martin J, Webb, Charles D, Hart, Lowell L, Gian, Victor G, Infante, Jeffrey R, Burris, Howard A, Hainsworth, John D

“…Abstract Background Epothilones, a new class of cytotoxic agents, have demonstrated activity in non-small-cell lung cancer (NSCLC). This phase II study…”
Get full text

A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer by Spigel, David R, Hainsworth, John D, Gandhi, Jitendra G, Gian, Victor G, Peyton, James D, West-Osterfield, Kimberly, Clark, Bobby L, Vazquez, Elizabeth R, Jones, Suzanne F, Burris, Howard A, Greco, F Anthony

“…Carboplatin and topotecan are commonly used in the treatment of small cell lung cancer (SCLC); however, there are no data for this combination in the…”
Get more information

A phase I trial of protracted oral fixed‐dose temozolomide by Jones, Suzanne F., Greco, F. Anthony, Gian, Victor G., Miranda, Fernando T., Raefsky, Eric L., Hainsworth, John D., Willcutt, Noel T., Beschorner, Aurelia F., Kennerly, Glyndon, Burris, Howard A.

“…BACKGROUND The current Phase I trial was conducted to determine the dose‐limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral…”
Get full text

Phase I. Trial of irinotecan and temozolomide in patients with solid tumors by Jones, Suzanne F, Gian, Victor G, Greco, F Anthony, Miranda, Fernando T, Shipley, Dianna L, Thompson, Dana S, Hainsworth, John D, Toomey, Mitchell A, Willcutt, Noel T, Burris, 3rd, Howard A

“…This phase I study was conducted to determine the dose-limiting toxicity, maximum tolerated doses, and recommended phase II doses of the combination of…”
Get more information

Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients by Hainsworth, John D, Mainwaring, Mark G, Thomas, Melodie, Porter, 3rd, Lester L, Gian, Victor G, Jones, Suzanne F, Greco, F Anthony

“…To evaluate the feasibility, toxicity, and efficacy of oral gefitinib (ZD1839, Iressa) in patients with refractory non-small-cell lung cancer (NSCLC) treated…”
Get full text

Phase II study of FOLFOXIRI plus panitumumab (pmab) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only by Zakari, Ahmed, Gian, Victor G., Meluch, Anthony Alan, Peyton, James D., Waterhouse, David Michael, Lipman, Andrew J., Boccia, Ralph V., Jones, Suzanne Fields, Bendell, Johanna C.

“…Abstract only…”
Get full text

COL1A1 copy number alterations detected in array-based comparative genomic hybridization (aCGH) inmyeloproliferative neoplasms: Implications for molecular pathogenesis and targeted therapy by Savona, Michael R., Chandra, Pranil, Ma, Zeqiang, Liang, Shile, Cooper, R. Seth, Raefsky, Eric, Gian, Victor G., Hockett, Richard, Berdeja, Jesus G., Lennon, P. Alan

“…Abstract only e22139 Background: Myeloproliferative neoplasms (MPNs) are a heterogeneous group of tumors marked by clonal proliferation of myeloid cells with…”
Get full text

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute by Thompson, Dana Shelton, Dudley, B. Stephens, Bismayer, John A., Gian, Victor G., Merritt, William McIver, Whorf, Robert C., Burris, Howard A., Hainsworth, John D.

“…Abstract only 5513 Background: The combination of paclitaxel and carboplatin is the most widely used chemotherapy regimen for patients (pts) with advanced…”
Get full text